Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX with or without toripalimab for conversion therapy in initially unresectable biliary tract cancer
ChiCTR2000039129Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of toripalimab, gemcitabine and oxaliplatin in biliary cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: conversion rate. Started May 2020; status: recruiting.
02
Drugs
toripalimabgemcitabineoxaliplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2000039129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039129.